Pembrolizumab and nivolumab as anti-PD-1 mAbs have shown remarkable anti-tumor activity in the treatment of head and neck squamous cell carcinoma (HNSCC), leading to their regulatory approval (9–11). The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.